

Please type a plus sign (+) inside this box →



PTO/SE/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/699,003
				Filing Date	October 26, 2009
				First Named Inventor	M. Rigdon Lentz
				Group Art Unit	3761
				Examiner Name	Leslie R. Deak
Sheet	1	of	3	Attorney Docket Number	LEN 101 CIP CON

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
		PCT	WO 03/056896		Molecular Staging, Inc.	07-17-2003		
		RU	2 130 069 (w/ Engl. Abstract)		Inst Ehlemento-organicheskikh S	05-10-1999		

Examiner's Signature	/Leslie Deak/	Date Considered	11/12/2009
-------------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

45100091

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH~~ ~~RD 111 GRC/ON~~ /LD/
077829/00009

077829/00009

Receipt date: 11/10/2009

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>		Complete if Known			
		Application Number	09/699,003		
		Filing Date	October 26, 2009		
		First Named Inventor	M. Rigdon Lentz		
		Group Art Unit	3761		
		Examiner Name	Leslie R. Deak		
Sheet	2	of	3	Attorney Docket Number	LEN 101 CIP CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ADOLF and FRÜHBEIS, "Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity.", <i>Cytokine</i> , 4(3):180-184 (1992).	
		BJORNBERG, et al., "Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors to soluble receptor forms", <i>Lymphokine Cytokine Res.</i> , 13(3):203-11 (1994).	
		COLMAN, et al., <u>Hemostasis and Thrombosis: Basic Principles and Clinical Practice</u> 2nd Ed., Colman, R.W., et al., p. 242-267 (J.B.Lippincott, Philadelphia, PA 1987).	
		GADDUCCI, et al., "Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNF), and soluble CD14 (sCD14) in epithelial ovarian cancer", <i>Gynecol Oncol</i> , 58(2):184-8 (1995).	
		GRELL, et al., "The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor", <i>Proc Natl Acad Sci U S A</i> , 95(2):570-5 (1998).	
		GROSEN, et al., "Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy", <i>Gynecol Oncol</i> , 50(1):68-77 (1993).	
		HASEGAWA, et al., "Increased soluble tumor necrosis factor receptor levels in the serum of elderly people", <i>Gerontology</i> , 46(4):185-8 (2000).	
		JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," <i>Arch Immunol Ther Exp (Warsz)</i> . 45(5-6):449-53 (1997).	
		JABLONSKA, et al., "Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients", <i>Eur Cytokine Netw</i> , 9(2):155-9 (1998).	
		LAUCELLA, et al., "Papel de las citoquinas en la resistencia y patologia durante la infeccion con <i>Trypanosoma cruzi</i> " <i>Revista Argentina de Microbiologia</i> , 28:99-109 (1996) (with English Abstract).	
		MACALLAN, et al., "Development of a novel TNF alpha ligand-receptor binding assay for screening NATCHEM Libraries", <i>J Recept Signal Transduct Res</i> , 17(1-3):521-9 (1997). (with English Abstract)	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

45100091

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /LD/

077829/00009

Receipt date: 11/10/2009

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		09/699,003	
				Filing Date		October 26, 2009	
				First Named Inventor		M. Rigdon Lentz	
				Group Art Unit		3761	
				Examiner Name		Leslie R. Deak	
Sheet	3	of	3	Attorney Docket Number		LEN 101 CIP CON	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MATSCHINER, et al., <u>Current Advances in Vitamin K Research</u> , pp. 135-140, (John W. Suttie, ed.) Elsevier Science Publishing Co., Inc., 1988.	
		NOPHAR, et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor", <i>EMBO J</i> , 9(10):3269-78 (1990).	
		ONSRUD, et al., "Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer", <i>Gynecol Oncol</i> , 57(2):183-7 (1995).	
		ONSRUD, et al., "Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer", <i>Tumour Biol</i> , 17(2):90-6 (1996).	
		TESAROVA, et al., "Soluble TNF and IL-2 receptors in patients with breast cancer", <i>Med Sci Monit</i> , 6(4):661-7 (2000).	

Examiner's Signature	/Leslie Deak/	Date Considered	12/03/2009
----------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+